Accommodating intraocular lens

Information

  • Patent Grant
  • 10772721
  • Patent Number
    10,772,721
  • Date Filed
    Friday, June 1, 2018
    6 years ago
  • Date Issued
    Tuesday, September 15, 2020
    3 years ago
Abstract
An accommodating intraocular lens (IOL) device adapted for implantation in the lens capsule of a subject's eye. The IOL device includes an anterior refractive optical element and a membrane coupled to the refractive optical element. The anterior refractive optical element and the membrane define an enclosed cavity configured to contain a fluid. At least a portion of the membrane is configured to contact a posterior area of the lens capsule adjoining the vitreous body of the subject's eye. The fluid contained in the enclosed cavity exerts a deforming or displacing force on the anterior refractive optical element in response to an anterior force exerted on the membrane by the vitreous body. The IOL device may further include a haptic system to position the anterior refractive optical element and also to engage the zonules and ciliary muscles to provide additional means for accommodation.
Description
FIELD OF THE INVENTION

The invention relates generally to an accommodating intraocular lens device and, more particularly, to an accommodating intraocular lens device configured for implantation in a lens capsule of a subject's eye.


BACKGROUND

A cataract is a clouding of the lens in the eye that affects vision. While most cataracts are related to aging, cataracts may also develop as a result of traumatic eye injury, glaucoma, diabetes, steroid use, and exposure to radiation, to name a few. If left untreated, cataracts progress to eventual vision loss and even complete blindness.


Cataracts are typically treated by surgically removing the clouded lens matrix and implanting a replacement artificial intraocular lens (IOL) in the lens capsule that remains. The first generation of implanted IOL devices comprised monofocal lenses, which provided vision correction at only a single distance. Thus, while monofocal lenses provided distance vision, corrective lenses were still required for reading.


Multifocal lenses for IOL devices were introduced to provide vision correction at more than one distance with the goal of obviating the need for additional corrective lenses required with the monofocal lenses. Multifocal lenses typically have areas of varying refractive power to provide vision at multiple distances (e.g., near, intermediate and far). One significant disadvantage to multi focal lenses is the possibility of visual distortions, particularly in the form of glare and halos around light sources at night.


Accommodating IOL devices have recently been introduced as yet another alternative IOL for use in cataract surgery. Accommodating IOL devices typically feature a monofocal lens that is configured to move forward and backward within the eye in response to the eye's natural mechanism of accommodation, thereby allowing the eye to focus on objects across a broad range of distances. Currently, Crystalens® by Bausch and Lomb is the only FDA-approved accommodating IOL on the market in the United States. This device comprises a relatively flat central lens and a pair hinged haptics protruding from the central lens. The haptics respond to the contraction and relaxation of the eye's ciliary muscles to move the central lens portion forward and backward within the eye to provide varying dioptres of power. The Crystalens® device relies solely on the eye's ciliary muscle function in order to provide accommodation. Moreover, because the profile of the Crystalens® device is substantially smaller than that of the natural lens capsule, implantation of this device is followed by shrinkage of the natural lens capsule about the device. As the natural lens capsule shrinks, the zonules are further stretched away from the ciliary muscles, with the attendant loss of the eye's accommodative range.


Dual-lens IOL devices have been developed with the goal of providing a broader range of accommodation that is closer to the eye's natural range. The dual-lens IOL devices typically feature an anterior and a posterior lens in a spaced relation and rely solely on the ciliary muscles to actuate the anterior and posterior lens closer or farther together to alter the distance between them. The varying distance between the anterior and posterior lens provides the accommodation. Examples of dual-lens IOL devices include U.S. Pat. No. 5,275,623, issued to Sarfarazi on Jan. 4, 1994 and U.S. Pub. No. 2006/0178741 to Zadno-Azizi et al., published on Aug. 10, 2006. Dual-lens IOL devices generally suffer the disadvantage of being more complicated in design and requiring larger incisions in the eye for implantation. While the dual-lens IOL devices may hold the potential for providing a greater range of accommodation, they represent a radical departure from the natural lens structure of the eye.


While accommodating IOL devices hold the promise of more fully restoring the natural range of vision for cataract patients, they still fail to substantially mimic the eye's natural mechanism of accommodation. This is primarily because they rely solely on the eye's ciliary muscles to provide the accommodation and fail to respond to other forces which influence the natural accommodative process.


BRIEF SUMMARY

Preferred embodiments of the accommodating intraocular lens (IOL) devices disclosed herein substantially mimic the eye's natural mechanism of accommodation by responding not only to the contraction/relaxation of the ciliary muscles but also to the influence of the viscous body, which bulges forward and exerts a force anteriorly to change the curvature of the lens capsule. Thus, by providing both bilateral displacement and changes in curvature, the accommodating IOL devices disclosed herein provide broader range of accommodation that approximates that found in the natural eye.


In one embodiment, an accommodating IOL device adapted for implantation in the lens capsule of a subject's eye is described. The accommodating IOL device comprises an anterior portion having a refractive optical element, an elastic posterior portion; and an enclosed cavity defined between the anterior and posterior portions. The enclosed cavity is configured to contain a volume of fluid to space apart the anterior and posterior portions. The posterior portion is configured to contact the posterior portion of the lens bag (prior to shrinkage of the lens capsule following implantation) which in turn contacts the vitreous body at least in the area at and surrounding the optical axis when the IOL device is implanted in the eye and the cavity contains the fluid. The posterior portion actuates in response to an anterior force exerted by the vitreous body, causing the fluid to exert a deforming or displacing force on the refractive optical element.


In accordance with a first aspect of this embodiment, the refractive optical element increases its degree of curvature in response to the anterior force and decreases its degree of curvature in the absence of the anterior force.


In accordance with a second aspect of this embodiment, the refractive optical element is resiliently biased to having a degree of curvature that is substantially equal to the degree of curvature of the anterior portion of the subject's natural lens capsule.


In accordance with a third aspect of this embodiment, the IOL device is biased to a configuration having a width that is substantially equal to the width of the unaccommodated natural lens capsule along the optical axis.


In accordance with a fourth aspect of this embodiment, the IOL device has an equatorial diameter that is substantially equal to the equatorial diameter of the subject's natural lens capsule in the unaccommodated state.


In accordance with a fifth aspect of this embodiment, the anterior portion is dimensioned to engage the zonules when the IOL device is implanted in the subject's eye.


In accordance with a sixth aspect of this embodiment, the IOL device further comprises a haptic system coupled to the anterior portion. The haptic system may be configured to substantially center the refractive optical element in the path of the optical axis when implanted in the subject's eye. Alternatively or additionally, the haptic system is configured to bilaterally displace the refractive optical element along the optical axis in response to the contraction and relaxation of the ciliary muscles when the IOL device is implanted in the subject's eye.


In accordance with a seventh aspect of this embodiment, the volume of fluid contained in the cavity is sufficient to space apart the anterior and posterior portions at a distance d3 along the optical axis that is substantially equal to the width of the subject's natural lens capsule along the optical axis d2 in the unaccommodated state.


In another embodiment, an accommodating IOL device adapted for implantation in the lens capsule of a subject's eye is described. The accommodating IOL device comprises an anterior refractive optical element and a membrane comprising a posterior surface. The membrane is coupled to the anterior optical element and defines an enclosed cavity configured to contain a volume of fluid. The posterior portion is configured to contact the posterior portion of the lens capsule which in turn contacts the vitreous body at least in an area at and surrounding the optical axis when the IOL device is implanted in the eye and the cavity contains the fluid. The fluid deforms the anterior refractive optical element in response to an anterior force exerted on the posterior surface by the vitreous body.


In accordance with a first aspect of this embodiment, the anterior optical element further comprises a self-sealing valve to permit the injection of the fluid.


In accordance with a second aspect of this embodiment, the fluid is viscoelastic.


In accordance with a third aspect of this embodiment, the fluid is an aqueous solution of saline or hyaluronic acid.


In accordance with a fourth aspect of this embodiment, the fluid has substantially the same viscosity as the vitreous humor.


In accordance with a fifth aspect of this embodiment, the fluid has substantially the same refractive index as the aqueous humor or the vitreous humor.


In accordance with a sixth aspect of this embodiment, the membrane is coupled to the anterior refractive optical element about its periphery.


In accordance with a seventh aspect of this embodiment, the anterior refractive optical element is contained within the enclosed cavity of the membrane.


In accordance with a eighth aspect of this embodiment, the posterior portion further comprises a reinforced portion.


In a further embodiment, a method for implanting an accommodating intraocular accommodating lens (IOL) device in a subject's eye is described. The method comprises introducing an IOL device in the lens capsule of the subject's eye through an incision in the subject's eye, wherein the IOL device comprises a refractive optical element coupled to an elastic membrane to define an internal cavity; positioning the IOL device within the lens capsule of the subject's eye to substantially center the refractive optical element along an optical axis; and injecting a volume of fluid into the internal cavity of the IOL device sufficient to cause the elastic membrane to contact the posterior portion of the lens capsule which in turn contacts the vitreous body in at least an area at and surrounding the optical axis.


Other objects, features and advantages of the described preferred embodiments will become apparent to those skilled in the art from the following detailed description. It is to be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration and not limitation. Many changes and modifications within the scope of the present invention may be made without departing from the spirit thereof, and the invention includes all such modifications.





BRIEF DESCRIPTION OF THE DRAWINGS

Preferred and non-limiting embodiments of the invention may be more readily understood by referring to the accompanying drawings in which:



FIGS. 1A and B are sectional views illustrating the certain anatomical features of the human eye with the lens in the unaccommodated and accommodated states, respectively.



FIGS. 2A, B and C are cut-away perspective, plan and cross-sectional views, respectively, of an embodiment of a refractive optical element coupled to a fluid-filled lens capsule.



FIGS. 3A and B are plan and side views, respectively, of an embodiment of a refractive optical element and haptic system.



FIGS. 4A, B and C are cut-away perspective, plan and cross-sectional views, respectively, of an embodiment of a refractive optical element and haptic system of FIGS. 3A-B coupled to a fluid filled lens capsule.



FIGS. 5A and B are plan and side views, respectively, of another embodiment of a refractive optical element and haptic system.



FIGS. 6A, B and C are cut-away perspective, plan and cross-sectional views, respectively, of another embodiment of a refractive optical element and haptic system of FIGS. 5A-B coupled to a fluid-filled lens capsule.



FIG. 7 depicts an embodiment of the intraocular lens device implanted in the posterior chamber of a human eye.





Like numerals refer to like parts throughout the several views of the drawings.


DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Specific, non-limiting embodiments of the present invention will now be described with reference to the drawings. It should be understood that such embodiments are by way of example only and merely illustrative of but a small number of embodiments within the scope of the present invention. Various changes and modifications obvious to one skilled in the art to which the present invention pertains are deemed to be within the spirit, scope and contemplation of the present invention as further defined in the appended claims.


As shown in FIGS. 1A-B, the human eye 100 comprises three chambers of fluid: the anterior chamber 112, the posterior chamber 120 and the vitreous chamber 160. The anterior chamber 112 corresponds generally to the space between the cornea 110 and the iris 114 and the posterior chamber 120 corresponds generally to the space bounded by the iris 114, the lens 130 and zonule fibers 140 connected to the periphery of the lens 130. The anterior chamber 112 and the posterior chamber 120 contain a fluid known as the aqueous humor, which flows therebetween through an opening that is defined by the iris 114, known as the pupil 116. Light enters the eye 100 through the pupil 116 and travels along a visual axis A-A, striking the retina 170 and thereby produce vision. The iris 114 regulates the amount of light entering the eye 100 by controlling the size of the pupil 116.


The vitreous chamber 160 is located between the lens 130 and the retina 170 and contains another fluid, known as the vitreous humor. The vitreous humor is much more viscous than the aqueous humor and is a transparent, colorless, gelatinous mass. Although much of the volume of the vitreous humor is water, it also contains cells, salts, sugars, vitrosin (a type of collagen), a network of collagen type II fibers with the glycosaminoglycan hyaluronic acid, and proteins. The vitreous has a viscosity two to four times that of pure water, giving it a gelatinous consistency. It also has a refractive index of 1.336.


Unlike the aqueous humor contained in the anterior and posterior chambers 112, 120 of the eye, which is continuously replenished, the vitreous humor is stagnant. The vitreous often becomes less viscous and may even collapse as part of the aging process. It is believed that the collagen fibers of the vitreous humor are held apart by electrical charges. With aging, these charges tend to reduce, and the fibers may clump together. Similarly, the vitreous humor may liquefy, a condition known as syneresis, allowing cells and other organic clusters to float freely within the vitreous humor. These allow floaters which are perceived in the visual field as spots or fibrous strands.


The lens 130 is a clear, crystalline protein membrane-like structure that is quite elastic, a quality that keeps it under constant tension via the attached zonules 140 and ciliary muscles 150. As a result, the lens 130 naturally tends towards a rounder configuration, a shape it must assume for the eye 100 to focus at a near distance as shown in FIG. 1B. By changing shape, the lens functions to change the focus distance of the eye so that it can focus on objects at various distances, thus allowing a real image of the object of interest to be formed on the retina.


As shown in FIGS. 1A and 1B, the lens 130 may be characterized as a capsule having two surfaces: an anterior surface 132 and a posterior surface 134. The anterior surface 132 faces the posterior chamber 120 and the posterior surface 134 faces the vitreous body 160. The posterior surface 134 contacts the vitreous body 160 in such a manner that fluid movements within the vitreous body 160 are communicated to the posterior surface 134 and may cause the shape of the lens 130 to change.


The eye's natural mechanism of accommodation is reflected by the changes in shape of the lens 130 and thus the extent to which it refracts light.



FIG. 1A shows the eye 100 in a relatively unaccommodated state, as may be the case when the eye is focusing at a distance. In an unaccommodated state, the ciliary muscles 150 relax, thereby increasing the diameter of its opening and causing the zonules to be pulled away from the visual axis A-A. This, in turn, causes the zonules 140 to radially pull on the periphery of the lens 130 and cause the lens 130 to flatten. As the shape of the lens 130 is flattened, its ability to bend or refract light entering the pupil is reduced. Thus, in an unaccommodated state, the lens 130 has a flatter surface, its diameter e1 along the equatorial axis B-B is lengthened and its thickness d1 along the visual axis A-A is decreased, all relative to the accommodated state (compare e2 and d2 in FIG. 1A).



FIG. 1B shows the eye 100 in a relatively accommodated state, as may be the case when the eye is focusing on a nearby object. In an accommodated state, the ciliary muscles 150 contract, and the contraction of the ciliary muscles 150 causes them to move in an anterior direction. This, in turn, reduces the stress on the zonules 140, thereby lessening the stress exerted by the zonules 140 on the lens 130. The lens 130 thereupon undergoes elastic recovery and rebounds to a more relaxed and accommodated state, in which the lens 130 has a more convex anterior surface, its diameter e2 along the equatorial axis B-B is decreased and its thickness a′2 along the visual axis A-A is increased relative to the unaccommodated state (compare e2 and d1 in FIG. 1A). Although FIG. 1B depicts the anterior and posterior surfaces 132, 134 of the lens capsule 130 as having roughly the same radius of curvature, it is believed that during accommodation, the radius of curvature for the anterior surface 132 increases and the radius of curvature of the posterior surface 134 is not significantly changed from its unaccommodated state.


As demonstrated by FIGS. 1A and 1B, accommodation results from the changes in shape of the lens 130, including the changes in the thickness of the lens capsule 130 (d1 vs. d2), changes in the diameter of the lens capsule 130 (e1 vs. e2) and the changes in the curvature of the anterior surface 132 of the lens capsule 130. While the ciliary muscles 150 are known to play a significant role in exerting these changes, it is believed that the vitreous body 160 also plays a significant role, primarily due to the nature of the contact between the posterior surface 134 of the lens 130 and the vitreous body 160, in which the posterior surface 134 responds to and transmits anterior fluid movement in the vitreous body 160 to effectuate changes in shape of the lens 130.



FIGS. 2A-C illustrate an embodiment of an accommodating IOL device 200 that may be implanted into the lens capsule 130 of the eye following cataract removal. The IOL device 200 is shown to comprise an optical element 210 and a flexible membrane 230 coupled to the optical element 210. The optical element 210 and the flexible membrane 230 together define an interior cavity 220 which may be filled with fluid. The optical element 210 may further optionally comprise an injection port 212 to permit the injection of the fluid to fill the cavity 220. In a preferred embodiment, the injection port 212 comprises a one-way value and is self-sealing. In another preferred embodiment, a separate plug 213 may be provided to seal off the injection port 212. While FIGS. 2-7 depict the injection port 212 as being located within the optical element 210, it is understood that the placement of the injection port 212 is not critical, so long as its placement does not impede vision.


The optical element 210 may be made of plastic, silicone, acrylic, or a combination thereof. In accordance with a preferred embodiment, the optical element 210 is made of poly(methyl methacrylate) (PMMA), which is a transparent thermoplastic, sometimes called acrylic glass. Because the optical element 210 is responsible for providing most, if not substantially all, of the refractive power of the IOC device, the optical element 210 is preferably sufficiently flexible so as to change its curvature in response to the contraction/relaxation of the anterior force that is exerted when the vitreous body bulges in the anterior direction.


In accordance with one embodiment, the optical element 210 is resiliently biased to a shape that approximates the shape of a natural and unaccommodated lens (see FIG. 1A). The optical element 210 accordingly increases its degree of curvature in response to the anterior force exerted by the vitreous body and is resiliently biased to a flatter configuration or a decreased degree of curvature, similar to the configuration of the natural lens in the unaccommodated state, in the absence of the anterior force.


In accordance with another embodiment, the optical element 210 is resiliently biased to a shape that approximates the shape of a natural and accommodated lens (see FIG. 1B). The optical element 210 accordingly is resiliently biased to a convex configuration similar to that of the natural lens in the accommodated state and assumes a less convex configuration as the ciliary muscles 150 relax and the tension of the zonules 140 on the lens capsule 130 increases.


In the embodiment shown in FIGS. 2A-C, the optical element 210 has a disk shape of sufficient diameter to engage the zonules 140 of the eye. As this dimension may differ from patient to patient, it is contemplated that the optical element 210 be provided in a range of sizes to fit a patient's anatomy. In other embodiments, the optical element 210 may further comprise a separate haptic system (FIGS. 3-6) to engage the zonules 140 of the eye. In these embodiments, the optical element 210 may have a diameter that is significantly smaller than the embodiments in which the optical element 210 directly engages the zonules 140 of the eye.


Regardless, in engaging the zonules 140, the IOL device responds to part of the accommodative mechanism of the eye in which the ciliary muscles 150 and the zonules 140 cause a bilateral movement of the optical element 210 along the optical axis to thereby provide part of the accommodating response.


The accommodating IOL device 200 is additionally configured to allow the optical element 210 change its shape in response to the forces exerted upon it by the vitreous body 160. This is achieved by providing a flexible optical element 210 and a fluid-filled flexible membrane 230 that is configured to transmit the anterior force of the vitreous body 160 during accommodation to affect the changes in the shape of the lens capsule 130. Preferably, in order to effectuate the transfer of the anterior movements of the vitreous body 160 upon the lens capsule 130, the membrane 230 contacts a substantial area of the posterior surface 134 of the lens capsule 130 and the membrane is sufficiently flexible and substantially devoid of any rigid material that would prevent it from responding to the anterior movements of the vitreous body 160. Thus, the accommodating IOL device 200 is distinguishable from prior art dual lens IOL devices in maintaining a flexible boundary between the lens capsule 130 and the vitreous body 160. In a particularly preferred embodiment, the membrane 230 is sufficiently thin and deformable so as not to impede the natural flexible boundary between the lens capsule 130 and the vitreous body 160.


Moreover, as explained above, there is a degree of shrinkage experienced by the lens capsule 130 after cataract surgery which depends on the profile and the dimension of the IOL device that is implanted in the lens capsule 130. As many of the prior art devices have a profile and/or dimension that is substantially different from the original lens capsule 130 (e.g., by having a smaller width d along the optical axis A-A or a smaller diameter along the equatorial axis B-B), a degree of shrinkage is expected which, in turn, affects the extent to which the lens capsule 130 is engaged to the vitreous body 160. In one preferred embodiment, the IOL device minimizes the degree to which this shrinkage occurs by significantly engaging the contours of the lens capsule 130, particularly the posterior surface 134 of the lens capsule 130 via the fluid filled cavity 220 defined by the optical element 210 and membrane 230. The membrane 230 is preferably configured to contact a substantial, if not substantially all, of the posterior surface 134 of the lens capsule 130 at implantation and before any significant shrinkage of the lens capsule 130 has occurred.


As explained above with respect to FIGS. 1A-B, during accommodation, the vitreous body 160 exerts a force in the anterior direction along the optical axis A-A and pushes the lens capsule 130 in the anterior direction. This, in turn, causes the anterior surface 132 of the lens capsule 130 to become more curved and thus to further refract the light.


Because the optical element 210 is responsible for providing most, if not substantially all, of the refractive power of the IOC device, the optical element 210 is preferably sufficiently flexible so as to change its curvature in response to the contraction/relaxation of the anterior force that is exerted when the vitreous body bulges in the anterior direction. In a preferred embodiment, the optical element 210 is resiliently biased to a shape that approximates the shape of a natural and unaccommodated lens (see FIG. 1A). The optical element 210 accordingly increases its degree of curvature response to the anterior force exerted by the vitreous body and is resiliently biased to a flatter configuration or a decreased degree of curvature, similar to the configuration of the natural lens in the unaccommodated state, in the absence of the anterior force.


The flexible membrane 230 may be constructed from any biocompatible elastomeric material. In a preferred embodiment, the flexible membrane 230 has an external surface that approximates the posterior surface of the lens capsule adjacent the vitreous body. The flexible membrane 230 is preferably configured and shaped to contact a substantial, if not the entire, area of the posterior surface of the lens capsule. In a particularly preferred embodiment, this point of contact is at and around the optical axis of the posterior surface.


The flexible membrane 230 is preferably configured to maximize this transfer of force from the vitreous body to the lens 122. As shown in FIGS. 1A and 1B, the anterior portion 132 of the lens 130 of the unaccommodated eye 100 in FIG. 1A has a lesser degree of curvature (i.e., is flatter) than that of the accommodated eye 100 of FIG. 1B. As the vitreous body is believed to exert an anterior force along the optical axis on the lens 122 to effectuate a greater degree of curvature, it is preferable to maximize transfer of force resulting from anterior vitreous movement onto the lens 122.


In accordance with one preferred embodiment, the flexible membrane 230 may have areas of greater and lesser elasticity so as to maximize the translation of the anterior movements of the vitreous body. For example, as shown in FIG. 2C, the flexible membrane 230 may comprise a central posterior portion 224 (corresponding to an area surrounding the optical axis A-A when the IOL device 200 is implanted) having greater elasticity than the adjacent circumferential portion 222. Having areas of reduced elasticity in the adjacent circumferential portion 222 may reduce radial expansion of the membrane 230 and allow the anterior force exerted by the vitreous body 170 to be more effectively translated and applied onto the optical element 210 by the fluid contained in the cavity 220 to thereby increase the curvature of the optical element 210.


In accordance with another preferred embodiment, the IOL device 200 may be configured to resiliently assume a shape having a width d3 that is substantially equal to the width the lens capsule 130 accommodated eye (see d2 of FIG. 1B) when it is implanted in the patient's eye. This may be achieved by constructing the IOL device 200 with resilient materials having some degree of shape memory and also by filling the cavity 220 with a volume of fluid sufficient to expand the flexible membrane 230 to the desired width, d3.


In accordance with a further preferred embodiment, the IOL device 200 comprises a single lens. The incorporation of additional lenses in the IOL device would likely interfere with the ability of the lens to deform (i.e., increase its curvature and provide additional diopters of power) to anterior vitreous movement.


The flexible membrane may preferably be made from a polyvinylidene fluoride (PDVF) material. PDVF is believed to allow for the transmission of lasers energy without, itself, becoming degraded. Optionally, a reinforced portion 234 of the flexible membrane 230 may optionally be provided to resist degradation upon the application of lasers of various wavelengths. In a preferred embodiment, the reinforced section 234 is positioned at an area on the membrane 230 corresponding to the optical axis A-A when the IOL device 200 is implanted in the subject's eye. Normally, after cataract surgery, a few of the residual epithelial cells in the lens capsule may migrate to a posterior surface of the bag resulting in various degrees of fibrosis which, in turn, may lead to undesired posterior capsule opacification (PCO). PCO is undesired, particularly at the optical path, and is typically treated by the application of laser pulses (e.g., YAG laser capsulotomy) to burn away the fibrotic membrane. Thus, a reinforced portion 234 may be provided on the membrane 230 as a protective mechanism against the potentially degradative effects of laser treatment on the membrane 230. In a preferred embodiment, the reinforced portion 234 remains flexible and is sized to correspond to the central area at and surrounding the optical axis A-A.


Once the IOL device is implanted in the lens capsule of the patient, a volume of fluid is injected into the cavity 220 via an injection port 212. In a preferred embodiment, the fluid is an aqueous solution of saline or hyaluronic acid and does not provide a significant, or any, contribution to the refractive power of the IOC device. Thus, the function of the fluid is primarily as a vehicle to transfer force resulting from the movement of the vitreous body 150 onto the optical element 210 to provide the accommodation. In a preferred embodiment, the fluid has a viscosity that is substantially the same as the vitreous humor. In another preferred embodiment, the fluid has a refractive index that is substantially the same as the aqueous humor or the vitreous humor.


The IOL device is distinguishable from prior art teachings in which the lens capsule is with various types of polymers, which are injected in liquid form and set with UV or other methods of polymerization. These at have been met with much difficulty as it is often difficult to control the refractive power provided by the polymerized polymers. Here, the refractive power is provided substantially, if not entirely, by the optical element 210 and the fluid that is contained within the cavity 220 does not contribute significantly, if at all, to providing the refractive power of the IOL device. Moreover, unlike the prior art polymers used to fill the lens capsule, the fluid is a relatively inert or biocompatible material, such as saline, or it alternatively contains a high molecular weight compound, such as hyaluronic acid, which does not readily leak from the IOL device 200.


The precise volume of fluid injected into the cavity 220 may differ based on the subject's anatomy, among other factors. The volume of fluid injected into the cavity 220 is not critical so long as it is sufficient to expand the membrane 230 such that the posterior portion of the membrane 230 substantially contacts the posterior portion of the lens capsule and engages the vitreous body of the subject's eye. As explained above, in one preferred embodiment, a volume of fluid is injected into the cavity 220 so as to provide a width d3 of the IOL device along the optical axis A-A substantially approximating the lens width d2 of the accommodated eye 100. In another preferred embodiment, a volume of fluid is injected into the cavity 220 so as to provide a width d3 of the IOL device along the optical axis AA substantially approximating the width d1 of the unaccommodated eye 100.


A haptic system may be incorporated with the IOL device to position the optical element 210 at the optical axis A-A when implanted in the subject's eye. As it is preferable to center the optical element 210 relative to the optical axis A-A, the haptic system preferably comprises a plurality of haptic members extending radially from the IOL device and engaging the zonules 140 surrounding the lens capsule 130 of the eye.



FIGS. 3A-B depict an optical element 210 comprising a pair of spring haptics 350 coupled to opposing sides of the optical element 210. As further shown in FIGS. 4A-C, a flexible membrane 230 may be coupled to the optical element 210/haptic 350 assembly along the periphery of the optical element 210. A seal is effectuated between the flexible membrane 230 and the periphery of the optical element 210 by laser welding and any other means known to those of skill in the art.


In another embodiment, the optical element 210 may be contained within a flexible membrane 230 that fully encloses the optical element 210. In accordance with this element, flexible membrane 230 has a bag or balloon-like configuration and the spring haptics 350 may be attached either (1) to the optical element 210 itself and protrude from a sealed opening in the flexible membrane 230 or (2) to the flexible membrane 230. Although FIGS. 3-4 depict a pair of spring haptics 350 extending radially from the optical element 210, it is understood that any number of spring haptics 350 may be provided so long as optical element 210 is centered about the optical axis A-A when the IOL device is implanted in the eye.



FIGS. 5A-B depict an optical element 210 comprising a pair of plate haptics 450 coupled to opposing sides of the optical element 210. The plate haptics 450 comprise a pair of plate members each comprising a first end 452 attached to the optical element 210 and a second end 456 configured to engage the zonules 140 of the eye 100 when implanted in the lens capsule 130. A hinge 454 is disposed between the first and second ends 452, 456, to allow lateral movement of the optical element 210 in the anterior and posterior directions as the ciliary muscles 150 relax and contract, respectively. As further shown in FIGS. 6A-C, a flexible membrane 230 may he coupled to the optical element 210/haptic 450 assembly along the periphery of the optical element 210.


In another embodiment, the optical element 210 may be contained within a flexible membrane 230 that fully encloses the optical element 210. In accordance with this element, the spring haptics 450 may be attached either (1) to the optical element 210 itself and protrude from a sealed opening in the flexible membrane 230 or (2) to the flexible membrane 230. Although FIGS. 5-6 depict a pair of plate haptics 450 extending radially from the optical element 210, it is understood that any number of plate haptics 450 may be provided so long as optical element 210 is centered about the optical axis A-A when the IOL device is implanted in the eye.



FIG. 7 depicts an embodiment of the accommodating IOL device implanted in the lens capsule 130 of the eye in an accommodated state. Because both the optical element 210 and the membrane 230 of the IOL device 200 is sufficiently flexible, it may be folded or rolled compactly prior to implantation, thereby requiring only a small incision of a few millimeters for insertion into the eye. As shown in FIG. 7, after the IOL device is implanted and the cavity 220 is filled with fluid, the IOL device is divided roughly in two: the anterior lens portion 210 facing the posterior capsule 120 and the posterior membrane portion 230 facing the vitreous body 160. The width d3 of the IOL device is resiliently biased to having a width that is roughly equal to the width of the natural lens capsule when it is in an accommodated state (see d2 of FIG. 1B). The posterior membrane portion 230 has an area of contact that approximates the surface area of the posterior portion 134 of the lens capsule 130 (See FIGS. 1A-B). Two or more haptics 550 are shown to protrude from the IOL device to substantially center the anterior lens portion 210 along the optical axis A-A.


The accommodated IOL device shown in FIG. 7 is implanted in the lens capsule of a subject's eye by introducing an IOL device in the lens capsule of the subject's eye through a small incision in the subject's eye, wherein the IOL device comprises a refractive optical element 210 coupled to an elastic membrane 230 to define an internal cavity 220. The IOL device is then positioned within the lens capsule 130 of the subject's eye to substantially center the refractive optical element 210 along an optical axis A-A. A volume of fluid is then injected into the internal cavity 220 of the IOL device sufficient to cause the elastic membrane 230 to contact the posterior portion of the lens capsule which, in turn, contacts the vitreous body in at least an area at and surrounding the optical axis A-A. In a preferred embodiment, the volume of fluid injected into the internal cavity 220 is sufficient to produce a width d3 of the IOL device along the optical axis A-A that is substantially equal to the width of a natural lens capsule in an accommodated state.


The invention described and claimed herein is not to be limited in scope by the specific preferred embodiments disclosed herein, as these embodiments are intended as illustrations of several aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

Claims
  • 1. An accommodating intraocular lens (IOL) device adapted for implantation in a lens capsule of a subject's eye, the IOL device comprising: an anterior biconvex lens;an elastic posterior portion;an enclosed cavity defined between a posterior surface of the anterior biconvex lens and the elastic posterior portion;a plate haptic coupled to a periphery of the elastic posterior portion and a periphery of the anterior biconvex lens, the haptic having a flat anterior surface and a flat posterior surface, a central plane of the plate haptic being aligned coplanar with a central plane of the anterior biconvex lens, the plate haptic comprising a hinge disposed between an outer end of the plate haptic and the periphery of the anterior biconvex lens that is configured to facilitate anterior and posterior axial movement of the anterior biconvex lens; andan injection port disposed through a periphery of the accommodating IOL;wherein the injection port is configured to be closed to contain a volume of fluid within the enclosed cavity to space apart the anterior biconvex lens and elastic posterior portion;wherein the elastic posterior portion is configured to contact a posterior area of the lens capsule adjoining a vitreous body at least in an area at and surrounding an optical axis of the subject when the IOL device is implanted in the eye and the enclosed cavity contains the volume of fluid; andwherein the posterior elastic portion actuates in response to an anterior force exerted by the vitreous body, causing the volume of fluid to exert a deforming and displacing force on the anterior biconvex lens.
  • 2. The accommodating IOL device of claim 1, wherein the anterior biconvex lens increases a degree of curvature in response to the anterior force exerted by the vitreous and decreases the degree of curvature in the absence of the anterior force.
  • 3. The accommodating IOL device of claim 1, the plate haptic comprising a narrowed portion between the outer end of the plate haptic and the periphery of the anterior biconvex lens.
  • 4. The accommodating IOL device of claim 3, wherein the plate haptic is configured to substantially center the anterior biconvex lens optical in a path of the optical axis of the subject when implanted in the subject's eye.
  • 5. The accommodating IOL device of claim 4, wherein the plate haptic is configured to bilaterally displace the anterior biconvex lens along the optical axis of the subject in response to a contraction and relaxation of a subject's ciliary muscles when the IOL device is implanted in the subject's eye.
  • 6. The accommodating IOL device of claim 1, wherein the injection port is configured to receive a plug to close the volume of fluid within the enclosed cavity.
  • 7. An accommodating intraocular lens (IOL) device adapted for implantation in a lens capsule of a subject's eye, the IOL device comprising: an anterior biconvex lens;an elastic portion coupled to the anterior biconvex lens;an enclosed cavity defined between the anterior biconvex lens and the elastic portion;a haptic coupled to a periphery of the anterior biconvex lens, the haptic having a flat anterior surface and a flat posterior surface, a central plane of the haptic being aligned coplanar with a central plane of the anterior biconvex lens; andan injection port disposed through a periphery of the accommodating IOL that is configured to closeto contain a volume of fluid within the enclosed cavity to space apart the anterior biconvex lens and the elastic portion;wherein when the elastic portion actuates in response to ocular force, the volume of fluid and the anterior biconvex lens shift in response to such actuation.
  • 8. The IOL device of claim 7, wherein the injection port extends into the enclosed cavity and is self-sealing.
  • 9. The IOL device of claim 7, wherein the haptic comprises: a first end directly coupled to the periphery of the anterior biconvex lens; and a second end that is configured to be compressed by ocular forces of the subject;wherein a hinge is disposed between the second end and the anterior biconvex lens such that the IOL device is configured to accommodate as ocular forces vary when ciliary muscles of the subject contract and relax.
  • 10. The IOL device of claim 7, wherein the elastic portion comprises a flexible membrane.
  • 11. The IOL device of claim 7, wherein the elastic portion comprises a central portion that is thicker than a peripheral thickness of the elastic portion, wherein central portion is configured to protect against the potentially degradative effects of laser treatment from YAG laser capsulotomy.
  • 12. The IOL device of claim 7, wherein the haptic is solid, not having an internal cavity configured to contain a volume of fluid between the flat anterior surface and the flat posterior surface.
  • 13. The IOL device of claim 7, wherein the haptic comprises a plate haptic.
  • 14. The IOL device of claim 13, further comprising a second haptic configured to couple the IOL device with a capsular bag of the subject's eye.
  • 15. The accommodating IOL device of claim 7, wherein the injection port is configured to receive a plug to close the volume of fluid within the enclosed cavity.
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 13/662,087, filed on Oct. 26, 2012, which is a continuation of International Application No. PCT/US2011/034197, filed Apr. 27, 2011, which in turn claims the benefit of U.S. Provisional Application No. 61/343,386, filed Apr. 27, 2010, the contents of which are incorporated herein by reference in their entireties into the present disclosure.

US Referenced Citations (416)
Number Name Date Kind
4032502 Lee et al. Jun 1977 A
4373218 Schachar Feb 1983 A
4512040 McClure Apr 1985 A
4585457 Kalb Apr 1986 A
4676791 LeMaster et al. Jun 1987 A
4720286 Bailey et al. Jan 1988 A
4731078 Stoy et al. Mar 1988 A
4822360 Deacon Apr 1989 A
4842601 Smith Jun 1989 A
4882368 Elias et al. Nov 1989 A
4888012 Horn et al. Dec 1989 A
4892543 Turley Jan 1990 A
4932966 Christie et al. Jul 1990 A
5035710 Nakada et al. Jul 1991 A
5059668 Fukuda et al. Oct 1991 A
5074876 Kelman Dec 1991 A
5091121 Nakada et al. Feb 1992 A
5152788 Isaacson et al. Oct 1992 A
5167883 Takemasa et al. Dec 1992 A
5171773 Chaffe et al. Dec 1992 A
5227447 Sato et al. Jul 1993 A
5236970 Christ et al. Aug 1993 A
5264522 Mize et al. Nov 1993 A
5275623 Sarfarazi Jan 1994 A
5278258 Gerace et al. Jan 1994 A
5312860 Mize et al. May 1994 A
5326506 Vanderbilt Jul 1994 A
5336487 Refojo et al. Aug 1994 A
5443506 Garabet Aug 1995 A
5447987 Sato et al. Sep 1995 A
5489302 Skottun Feb 1996 A
5583178 Oxman et al. Dec 1996 A
5607472 Thompson Mar 1997 A
5665794 Maxson et al. Sep 1997 A
5854310 Maxson Dec 1998 A
6071439 Bawa et al. Jun 2000 A
6117171 Skottun Sep 2000 A
6197057 Peyman et al. Mar 2001 B1
6361561 Huo et al. Mar 2002 B1
6551354 Ghazizadeh et al. Apr 2003 B1
6616691 Tran Sep 2003 B1
6695881 Peng et al. Feb 2004 B2
6730123 Klopotek May 2004 B1
6836374 Esch et al. Dec 2004 B2
6855164 Glazier Feb 2005 B2
6858040 Nguyen et al. Feb 2005 B2
6860601 Shadduck Mar 2005 B2
6926736 Peng et al. Aug 2005 B2
6930838 Schachar Aug 2005 B2
6935743 Shadduck Aug 2005 B2
6966649 Shadduck Nov 2005 B2
6969403 Peng et al. Nov 2005 B2
7041134 Nguyen et al. May 2006 B2
7063723 Ran Jun 2006 B2
7068439 Esch et al. Jun 2006 B2
7122053 Esch Oct 2006 B2
7150760 Zhang Dec 2006 B2
7217288 Esch et al. May 2007 B2
7220279 Nun May 2007 B2
7223288 Zhang et al. May 2007 B2
7226478 Ting et al. Jun 2007 B2
7229475 Glazier Jun 2007 B2
7238201 Portney et al. Jul 2007 B2
7247168 Esch et al. Jul 2007 B2
7261737 Esch et al. Aug 2007 B2
7264351 Shadduck Sep 2007 B2
7276619 Kunzler et al. Oct 2007 B2
7278739 Shadduck Oct 2007 B2
7316713 Zhang Jan 2008 B2
7416562 Gross Aug 2008 B2
7438723 Esch Oct 2008 B2
7452377 Watling et al. Nov 2008 B2
7453646 Lo Nov 2008 B2
7485144 Esch Feb 2009 B2
7591849 Richardson Sep 2009 B2
7637947 Smith et al. Dec 2009 B2
7662179 Sarfarazi Feb 2010 B2
7675686 Lo et al. Mar 2010 B2
7753953 Yee Jul 2010 B1
7776088 Shadduck Aug 2010 B2
7780729 Nguyen et al. Aug 2010 B2
7815678 Nun Oct 2010 B2
7842087 Nun Nov 2010 B2
7854764 Nun Dec 2010 B2
7857850 Mentak et al. Dec 2010 B2
7981155 Cumming Jul 2011 B2
7985253 Cumming Jul 2011 B2
7986465 Lo et al. Jul 2011 B1
7998198 Angelopoulos et al. Aug 2011 B2
7998199 Nun Aug 2011 B2
8012204 Weinschenk, III et al. Sep 2011 B2
8018658 Lo Sep 2011 B2
8034106 Mentak et al. Oct 2011 B2
8034107 Stenger Oct 2011 B2
8038711 Clarke Oct 2011 B2
8048155 Shadduck Nov 2011 B2
8052752 Woods et al. Nov 2011 B2
8062361 Nguyen et al. Nov 2011 B2
8070806 Khoury Dec 2011 B2
8158712 Your Apr 2012 B2
8182531 Hermans et al. May 2012 B2
8187325 Zadno-Azizi et al. May 2012 B2
8197541 Schedler Jun 2012 B2
8216306 Coroneo Jul 2012 B2
8246679 Nguyen et al. Aug 2012 B2
8254034 Shields et al. Aug 2012 B1
8257827 Shi et al. Sep 2012 B1
8273123 Nun Sep 2012 B2
8303656 Shadduck Nov 2012 B2
8314927 Choi et al. Nov 2012 B2
8320049 Huang et al. Nov 2012 B2
8328869 Smiley et al. Dec 2012 B2
8361145 Scholl et al. Jan 2013 B2
8377124 Hong et al. Feb 2013 B2
8398709 Nun Mar 2013 B2
8414646 De Juan, Jr. et al. Apr 2013 B2
8425597 Glick et al. Apr 2013 B2
8425599 Shadduck Apr 2013 B2
8430928 Liao Apr 2013 B2
8447086 Hildebrand et al. May 2013 B2
8454688 Esch et al. Jun 2013 B2
8475529 Clarke Jul 2013 B2
8496701 Hermans et al. Jul 2013 B2
8500806 Phillips Aug 2013 B1
8545556 Woods et al. Oct 2013 B2
8579972 Rombach Nov 2013 B2
8585758 Woods Nov 2013 B2
8608799 Blake Dec 2013 B2
8608800 Portney Dec 2013 B2
8613766 Richardson et al. Dec 2013 B2
8647384 Lu Feb 2014 B2
8657878 Mentak et al. Feb 2014 B2
8668734 Hildebrand et al. Mar 2014 B2
8690942 Hildebrand et al. Mar 2014 B2
8715345 DeBoer et al. May 2014 B2
8715346 De Juan, Jr. et al. May 2014 B2
8734509 Mentak et al. May 2014 B2
8771347 DeBoer et al. Jul 2014 B2
8814934 Geraghty et al. Aug 2014 B2
8834565 Nun Sep 2014 B2
8858626 Noy Oct 2014 B2
8867141 Pugh et al. Oct 2014 B2
8900298 Anvar et al. Dec 2014 B2
8900300 Wortz Dec 2014 B1
8956408 Smiley et al. Feb 2015 B2
8968396 Matthews et al. Mar 2015 B2
8968399 Ghabra Mar 2015 B2
8992609 Shadduck Mar 2015 B2
9005282 Chang et al. Apr 2015 B2
9005283 Nguyen et al. Apr 2015 B2
9034035 Betser et al. May 2015 B2
9044317 Hildebrand et al. Jun 2015 B2
9072600 Tran Jul 2015 B2
9090033 Carson et al. Jul 2015 B2
9095424 Kahook et al. Aug 2015 B2
9125736 Kahook et al. Sep 2015 B2
9186244 Silvestrini et al. Nov 2015 B2
9198752 Woods Dec 2015 B2
9277987 Smiley et al. Mar 2016 B2
9277988 Chu Mar 2016 B1
9289287 Kahook et al. Mar 2016 B2
9326846 Devita Gerardi et al. May 2016 B2
9333072 Ichikawa May 2016 B2
9358103 Wortz et al. Jun 2016 B1
9364316 Kahook et al. Jun 2016 B1
9387069 Kahook et al. Jul 2016 B2
9421088 Kahook et al. Aug 2016 B1
9427312 DeBoer et al. Aug 2016 B2
9433497 DeBoer et al. Sep 2016 B2
9456895 Shadduck Oct 2016 B2
9486311 Argento et al. Nov 2016 B2
9610155 Matthews Apr 2017 B2
9622852 Simonov et al. Apr 2017 B2
9629712 Stenger Apr 2017 B2
9636213 Brady May 2017 B2
9655716 Cumming May 2017 B2
9681946 Kahook et al. Jun 2017 B2
9693858 Hildebrand et al. Jul 2017 B2
9713526 Rombach Jul 2017 B2
9713527 Nishi et al. Jul 2017 B2
9717589 Simonov et al. Aug 2017 B2
9744027 Jansen Aug 2017 B2
9744028 Simonov et al. Aug 2017 B2
9795473 Smiley et al. Oct 2017 B2
9808339 Dorronsoro Diaz et al. Nov 2017 B2
9814568 Ben Nun Nov 2017 B2
9814570 Robert et al. Nov 2017 B2
9820849 Jansen Nov 2017 B2
9848980 McCafferty Dec 2017 B2
9855137 Smiley et al. Jan 2018 B2
9855139 Matthews et al. Jan 2018 B2
9861469 Simonov et al. Jan 2018 B2
9872762 Scholl et al. Jan 2018 B2
9872763 Smiley et al. Jan 2018 B2
9877825 Kahook et al. Jan 2018 B2
9883940 Nishi et al. Feb 2018 B2
9925039 Sohn et al. Mar 2018 B2
9925040 Kahook et al. Mar 2018 B2
9931202 Borja et al. Apr 2018 B2
9987126 Borja et al. Jun 2018 B2
10004596 Brady et al. Jun 2018 B2
10028824 Kahook et al. Jul 2018 B2
10045844 Smiley et al. Aug 2018 B2
10080648 Kahook et al. Sep 2018 B2
10111745 Silvestrini et al. Oct 2018 B2
10159564 Brady et al. Dec 2018 B2
10195018 Salahieh et al. Feb 2019 B2
10195020 Matthews Feb 2019 B2
10526353 Silvestrini Jan 2020 B2
20020005344 Heidlas et al. Jan 2002 A1
20020055776 Juan, Jr. et al. May 2002 A1
20020071856 Dillingham et al. Jun 2002 A1
20020120329 Lang et al. Aug 2002 A1
20030093149 Glazier May 2003 A1
20030105522 Glazier Jun 2003 A1
20030109926 Portney Jun 2003 A1
20030158295 Fukuda et al. Aug 2003 A1
20040082993 Woods Apr 2004 A1
20040082994 Woods et al. Apr 2004 A1
20040111152 Kelman Jun 2004 A1
20040148023 Shu Jul 2004 A1
20040162612 Portney et al. Aug 2004 A1
20040169816 Esch Sep 2004 A1
20040249455 Tran Dec 2004 A1
20050021139 Shadduck Jan 2005 A1
20050071002 Glazier Mar 2005 A1
20050107873 Zhou May 2005 A1
20050137703 Chen Jun 2005 A1
20050251253 Gross Nov 2005 A1
20050251254 Brady et al. Nov 2005 A1
20050267575 Nguyen et al. Dec 2005 A1
20060041307 Esch et al. Feb 2006 A1
20060047339 Brown Mar 2006 A1
20060069178 Rastogi et al. Mar 2006 A1
20060074487 Gilg Apr 2006 A1
20060111776 Glick et al. May 2006 A1
20060134173 Liu et al. Jun 2006 A1
20060135477 Haitjema et al. Jun 2006 A1
20060212116 Woods Sep 2006 A1
20060238702 Glick et al. Oct 2006 A1
20060241752 Israel Oct 2006 A1
20070016293 Tran Jan 2007 A1
20070032868 Woods et al. Feb 2007 A1
20070050024 Zhang Mar 2007 A1
20070050025 Nguyen et al. Mar 2007 A1
20070078515 Brady et al. Apr 2007 A1
20070088433 Esch et al. Apr 2007 A1
20070100445 Shadduck May 2007 A1
20070106377 Smith et al. May 2007 A1
20070118216 Pynson May 2007 A1
20070129798 Chawdhary Jun 2007 A1
20070129799 Schedler Jun 2007 A1
20070129800 Cumming Jun 2007 A1
20070129801 Cumming Jun 2007 A1
20070132949 Phelan Jun 2007 A1
20070213817 Esch et al. Sep 2007 A1
20070260308 Tran Nov 2007 A1
20070260310 Richardson Nov 2007 A1
20080015689 Esch et al. Jan 2008 A1
20080033547 Chang et al. Feb 2008 A1
20080046074 Smith et al. Feb 2008 A1
20080046075 Esch et al. Feb 2008 A1
20080046077 Cumming Feb 2008 A1
20080051886 Lin Feb 2008 A1
20080154364 Richardson et al. Jun 2008 A1
20080200982 Your Aug 2008 A1
20080269887 Cumming Oct 2008 A1
20080300680 Nun Dec 2008 A1
20080306587 Your Dec 2008 A1
20080306588 Smiley et al. Dec 2008 A1
20080306589 Donitzky et al. Dec 2008 A1
20090005865 Smiley et al. Jan 2009 A1
20090027661 Choi et al. Jan 2009 A1
20090043384 Niwa et al. Feb 2009 A1
20090116118 Frazier et al. May 2009 A1
20090125106 Weinschenk, III et al. May 2009 A1
20090149952 Shadduck Jun 2009 A1
20090198326 Zhou et al. Aug 2009 A1
20090204209 Tran Aug 2009 A1
20090204210 Pynson Aug 2009 A1
20090264998 Mentak Oct 2009 A1
20090292355 Boyd et al. Nov 2009 A1
20090319040 Khoury Dec 2009 A1
20100004742 Cumming Jan 2010 A1
20100055449 Ota Mar 2010 A1
20100057095 Khuray et al. Mar 2010 A1
20100094412 Wensrich Apr 2010 A1
20100094413 Rombach et al. Apr 2010 A1
20100131058 Shadduck May 2010 A1
20100131059 Callahan et al. May 2010 A1
20100179653 Argento et al. Jul 2010 A1
20100204787 Noy Aug 2010 A1
20100211169 Stanley et al. Aug 2010 A1
20100228344 Shadduck Sep 2010 A1
20100288346 Esch Sep 2010 A1
20100324672 Esch et al. Dec 2010 A1
20100324674 Brown Dec 2010 A1
20110029074 Reisin et al. Feb 2011 A1
20110071628 Gross et al. Mar 2011 A1
20110118834 Lo et al. May 2011 A1
20110118836 Jain May 2011 A1
20110208301 Anvar et al. Aug 2011 A1
20110224788 Webb Sep 2011 A1
20110282442 Scholl et al. Nov 2011 A1
20110288638 Smiley et al. Nov 2011 A1
20120016473 Brady et al. Jan 2012 A1
20120035724 Clarke Feb 2012 A1
20120071972 Zhao Mar 2012 A1
20120078364 Stenger Mar 2012 A1
20120095125 Hu et al. Apr 2012 A1
20120232649 Cuevas Sep 2012 A1
20120245683 Christie et al. Sep 2012 A1
20120253458 Geraghty et al. Oct 2012 A1
20120253459 Reich et al. Oct 2012 A1
20120290084 Coroneo Nov 2012 A1
20120296423 Caffey Nov 2012 A1
20120296424 Betser Nov 2012 A1
20120310341 Simonov et al. Dec 2012 A1
20120310343 Van Noy Dec 2012 A1
20130006353 Betser et al. Jan 2013 A1
20130035760 Portney Feb 2013 A1
20130038944 Chang et al. Feb 2013 A1
20130060331 Shadduck Mar 2013 A1
20130110234 DeVita et al. May 2013 A1
20130110235 Shweigerling May 2013 A1
20130116781 Nun May 2013 A1
20130131794 Smiley et al. May 2013 A1
20130190867 Peyman Jul 2013 A1
20130231741 Clarke Sep 2013 A1
20130250239 Hildebrand et al. Sep 2013 A1
20130268070 Esch et al. Oct 2013 A1
20130297018 Brady et al. Nov 2013 A1
20130317607 DeBoer et al. Nov 2013 A1
20130317608 Hermans et al. Nov 2013 A1
20140012277 Matthews et al. Jan 2014 A1
20140058507 Reich et al. Feb 2014 A1
20140085726 Portney Mar 2014 A1
20140100654 Portney et al. Apr 2014 A1
20140107459 Lind et al. Apr 2014 A1
20140111765 DeBoer et al. Apr 2014 A1
20140121768 Simpson May 2014 A1
20140135917 Glazier May 2014 A1
20140135918 De Juan, Jr. et al. May 2014 A1
20140142558 Culbertson et al. May 2014 A1
20140172092 Carson et al. Jun 2014 A1
20140180404 Tram Jun 2014 A1
20140180405 Weinschenk, III et al. Jun 2014 A1
20140180406 Simpson Jun 2014 A1
20140180407 Sohn et al. Jun 2014 A1
20140180410 Gerardi Jun 2014 A1
20140227437 DeBoer et al. Aug 2014 A1
20140228949 Argento et al. Aug 2014 A1
20140249625 Shadduck Sep 2014 A1
20140257478 McCafferty Sep 2014 A1
20140257479 McCafferty Sep 2014 A1
20140309734 Sohn et al. Oct 2014 A1
20150087743 Anvar et al. Mar 2015 A1
20150105760 Rao et al. Apr 2015 A1
20150127102 Wortz May 2015 A1
20150173892 Borja et al. Jun 2015 A1
20150202041 Shadduck Jul 2015 A1
20150216652 Jansen Aug 2015 A1
20150238310 Matthews et al. Aug 2015 A1
20150366656 Wortz et al. Dec 2015 A1
20160000558 Honigsbaum Jan 2016 A1
20160008126 Salahieh et al. Jan 2016 A1
20160051361 Phillips Feb 2016 A1
20160058553 Salahieh et al. Mar 2016 A1
20160074154 Woods Mar 2016 A1
20160184089 Dudee et al. Jun 2016 A1
20160184092 Smiley et al. Jun 2016 A1
20160208138 Nishijima et al. Jul 2016 A1
20160256265 Borja et al. Sep 2016 A1
20160262875 Smith et al. Sep 2016 A1
20160281019 Deklippel et al. Sep 2016 A1
20160287380 Shi et al. Oct 2016 A1
20160317287 Silvestrini et al. Nov 2016 A1
20170020662 Shadduck Jan 2017 A1
20170049561 Smiley et al. Feb 2017 A1
20170049562 Argento et al. Feb 2017 A1
20170216021 Brady Aug 2017 A1
20170247525 Silverstrini et al. Aug 2017 A1
20170290658 Hildebrand et al. Oct 2017 A1
20170319332 Kahook et al. Nov 2017 A1
20170342096 Silvestrini Nov 2017 A1
20170348095 Wortz et al. Dec 2017 A1
20180014928 Kahook et al. Jan 2018 A1
20180028308 Smiley et al. Feb 2018 A1
20180110613 Wortz et al. Apr 2018 A1
20180125640 Smiley et al. May 2018 A1
20180132997 Smiley et al. May 2018 A1
20180147051 Scholl et al. May 2018 A1
20180153682 Hajela et al. Jun 2018 A1
20180161152 Argento et al. Jun 2018 A1
20180161153 Kahook et al. Jun 2018 A1
20180177589 Argento et al. Jun 2018 A1
20180177639 Rao et al. Jun 2018 A1
20180256315 Hildebrand et al. Sep 2018 A1
20180271642 Wortz et al. Sep 2018 A1
20180271645 Brady et al. Sep 2018 A1
20180280135 Otts Oct 2018 A1
20180296323 Olcina Portilla Oct 2018 A1
20180307061 State et al. Oct 2018 A1
20180318068 Otts et al. Nov 2018 A1
20180344453 Brady Dec 2018 A1
20180368971 Zacher et al. Dec 2018 A1
20180368973 Wortz et al. Dec 2018 A1
20180368974 Kahook et al. Dec 2018 A1
20190015198 Kuiper Jan 2019 A1
20190021848 Kahook et al. Jan 2019 A1
20190069989 Otts et al. Mar 2019 A1
20190076239 Wortz et al. Mar 2019 A1
20190076243 Hadba et al. Mar 2019 A1
20190083235 Wortz Mar 2019 A1
20190099263 Brady et al. Apr 2019 A1
20190374334 Brady et al. Dec 2019 A1
Foreign Referenced Citations (67)
Number Date Country
20 2010 003217 Aug 2011 DE
0356050 Feb 1990 EP
0766540 Aug 1999 EP
1881818 Jul 2015 EP
H09-150002 Jun 1997 JP
2005-511201 Apr 2005 JP
2006-511245 Apr 2006 JP
2006-516002 Jun 2006 JP
2010-514507 May 2010 JP
2013-047290 Mar 2013 JP
WO 9217132 Oct 1992 WO
WO 9929266 Jun 1999 WO
WO 2001034067 May 2001 WO
WO 2004037127 May 2004 WO
WO 2004052242 Jun 2004 WO
WO 2004054471 Jul 2004 WO
WO 2004072689 Aug 2004 WO
WO 2006047383 May 2006 WO
WO 2007005778 Jan 2007 WO
WO 2007047529 Apr 2007 WO
WO 2007047530 Apr 2007 WO
WO 2008024766 Feb 2008 WO
WO 2008031231 Mar 2008 WO
WO 2008077040 Jun 2008 WO
WO 2008082957 Jul 2008 WO
WO 2008103798 Aug 2008 WO
WO 2009015161 Jan 2009 WO
WO 2009015226 Jan 2009 WO
WO 2009015234 Jan 2009 WO
WO 2009015240 Jan 2009 WO
WO 2009064876 May 2009 WO
WO 2010010565 Jan 2010 WO
WO 2010081093 Jul 2010 WO
WO 2011026068 Mar 2011 WO
WO 2011106435 Sep 2011 WO
WO 2011137191 Nov 2011 WO
WO 2012006616 Jan 2012 WO
WO 2012129407 Sep 2012 WO
WO 2013016804 Feb 2013 WO
WO 2013070924 May 2013 WO
WO 2013142323 Sep 2013 WO
WO 2013166068 Nov 2013 WO
WO 2013180254 Dec 2013 WO
WO 2013190130 Dec 2013 WO
WO 2014099630 Jun 2014 WO
WO 2014145562 Sep 2014 WO
WO 2014152017 Sep 2014 WO
WO 2014197170 Dec 2014 WO
WO 2015066502 May 2015 WO
WO 2015066532 May 2015 WO
WO 2015126604 Aug 2015 WO
WO 2016018932 Feb 2016 WO
WO 2016033217 Mar 2016 WO
WO 2016122805 Aug 2016 WO
WO 2016201351 Dec 2016 WO
WO 2017079449 May 2017 WO
WO 2017079733 May 2017 WO
WO 2017087358 May 2017 WO
WO 2017096087 Jun 2017 WO
WO 2017192855 Nov 2017 WO
WO 2018081595 May 2018 WO
WO 2018119408 Jun 2018 WO
WO 2018167099 Sep 2018 WO
WO 2018222579 Dec 2018 WO
WO 2018227014 Dec 2018 WO
WO 2019005859 Jan 2019 WO
WO 2019027845 Feb 2019 WO
Non-Patent Literature Citations (11)
Entry
International Search Report and Written Opinion dated Jul. 14, 2011 for PCT/US2011/034197 in 7 pages.
Ehrmann, et al., “Biomechanical analysis of the accommodative apparatus in primates”, Clinical and Experimental Optometry, May 2008, vol. 91, Issue 3, pp. 302-312.
Ehrmann, et al., “Ex Vivo Accommodation Simulator II—Concept and Preliminary Results”, Proceedings of SPIE vol. 5314, Ophthalmic Technologies XIV, Jul. 2004, pp. 48-58.
Gabel, et al., “Silicone oil with high specific gravity for intraocular use”, British Journal of Ophthalmology, Apr. 1987, vol. 71, 262-267.
Ghallagher-Wetmore, et al., “Supercritical fluid processing: a new dry technique for photoresist developing”, SPIE's 1995 Symposium on Microlithography, 1995, vol. 2438, 16 pages.
Lane, et al., “Comparison of the biomechanical behavior of foldable intraocular lenses”, Journal of Cataract Refract Surg, Nov. 2004, vol. 30, pp. 2397-2402.
Nakamura, et al., “Analysis and Fractionation of Silicone and Fluorosilicone Oils for Intraocular Use”, Investigative Ophthalmology & Visual Science, vol. 31, No. 10, Oct. 1990, 2059-2069.
National Center for Biotechnology Information. PubChem Substance Database; SID=184590955, https://pubchem.ncbi.nlm.nih.gov/substance/184590955 (accessed Sep. 20, 2017).
Zhang, et al., “Fluidic adaptive lens with high focal length tunability”, Applied Physics Letters, May 2003, vol. 82, No. 19, pp. 3171-3172.
Zhang, et al., “Integrated fluidic adaptive zoom lens”, Optics Letters, Dec. 2004, vol. 29, No. 24, pp. 2855-2857.
Zhao, et al., “Strategies for Supercritical CO2 Fractionation of Polydimethylsiloxane,” Journal of Applied Polymer Science, 1995, vol. 55, 773-778.
Related Publications (1)
Number Date Country
20190000612 A1 Jan 2019 US
Provisional Applications (1)
Number Date Country
61343386 Apr 2010 US
Continuations (2)
Number Date Country
Parent 13662087 Oct 2012 US
Child 15995671 US
Parent PCT/US2011/034197 Apr 2011 US
Child 13662087 US